ClinicalTrials.gg
RecruitingNCT07951554Updated Nov 20, 2026

INTEREST OF CAPA-MEDIUM CULTURE MEDIUM DURING IN VITRO MATURATION FOR THE MANAGEMENT OF POLYCYSTIC OVARY SYNDROME IN ASSISTED REPRODUCTIVE TECHNOLOGY

An interventional study of in vitro maturation (IVM) of oocytes in PCOS (Polycystic Ovary Syndrome), sponsored by Hospital St. Joseph, Marseille, France. Recruiting at 1 site in France. Open to female participants aged 18 Years to 37 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Hospital St. Joseph, Marseille, France · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Apr 2026, registered Nov 2026).
  • Started Apr 2026; still recruiting 7 months later.
Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 37 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 21 studies in Polycystic Ovary Syndrome with a site in France — 9 open to participants now, 10 under way, 1 of them phase 3. Polycystic Ovary Syndrome · France.

Planned enrollment
11th of 13
30 · median 52
Started
2026
with 4 others
No phase
8 of 21
5 open now
Registered
21st of 21
by date
Lead sponsor
1 of 21
Hospital St. Joseph, Marseille, France

Among the 21 studies in Polycystic Ovary Syndrome with a site in France, this one is the 11th largest by planned enrollment of the 13 interventional ones that give a count, is one of 5 that started in 2026, is one of 8 with no phase, and was the 21st registered.

Polycystic Ovary Syndrome

959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.

Browse Polycystic Ovary Syndrome studies →

Open to participants now

9 of the 21 studies in Polycystic Ovary Syndrome with a site in France are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 37 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Polycystic Ovary Syndrome with a site in France, or all of them as a file.
02

Study summary

The OPKAPAMIV study is a monocentric, open-label clinical trial evaluating the effectiveness of CAPA-MEDIUM culture medium for in vitro maturation (IVM) of oocytes in women with polycystic ovary syndrome (PCOS) undergoing assisted reproductive technology. The primary objective is to achieve a 60% maturation rate of immature cumulus-oocyte complexes (COCs) retrieved from PCOS patients. Secondary objectives include assessing fertilization, blastulation, implantation, pregnancy, and live birth rates, as well as monitoring the health of children born from these procedures. The study also compares outcomes between fresh and vitrified oocytes. The protocol aims to improve safety and success rates for PCOS patients, reducing the risk of ovarian hyperstimulation syndrome by avoiding conventional ovarian stimulation.

03

Conditions studied

  • PCOS (Polycystic Ovary Syndrome)

Keywords

  • PCOS (Polycystic Ovary Syndrome), in vitro maturation (IVM) of oocytes
04

Who can participate

Ages eligible
18 Years to 37 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 18 to 37 years (inclusive).
  • Men aged 18 to 58 years (inclusive).
  • PCOS diagnosis based on modified Rotterdam criteria.
  • At least one previous IVF +/- ICSI cycle with failed stimulation or oocyte retrieval showing poor oocyte and/or embryo quality.
  • Antral follicle count (AFC) ≥ 50.
  • Signed (free, informed, and written consent).
  • Affiliation with a social security system or being a beneficiary of such a system.

Exclusion criteria

Exclusion Criteria:

  • Abnormal karyotype.
  • Endometriosis grade >2.
  • to pregnancy.
  • Contraindication to general anesthesia.
  • Difficult oocyte retrieval predicted by ultrasound (e.g., >30).
  • Women with contraindications to ART or associated pathologies, including : - Hypertension (HTN), risk of eclampsia, viral infection risk, family genetic disorders, diabetes, uterine anomalies (septations, synechiae/adhesions, adenomyosis), Any other condition deemed a contraindication by the investigator.
  • Severe male infertility (cryptozoospermia or azoospermia).
  • Individuals under legal guardianship or curatorship.
  • Vulnerable populations: Persons deprived of liberty, individuals receiving psychiatric care, persons admitted to a healthcare or social institution, adults under legal protection measures, and individuals unable to express their consent.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    CAPA-MEDIUM In Vitro Maturation (IVM) for PCOS Patients in Assisted Reproductive Technology

    Other: in vitro maturation (IVM) of oocytes

Interventions

  • Otherin vitro maturation (IVM) of oocytes

    In Vitro Maturation (IVM) Protocol Phase 1 (CAPA-medium): The cumulus-oocyte complexes (COCs) are incubated for 24 hours in an enriched medium (CAPA-medium) containing HSA, insulin, estradiol, FSH, amphiregulin, and CNP, mimicking the natural follicular environment. Phase 2 (IVM-medium): After 24 hours, the COCs are transferred into another medium (IVM-medium) for an additional 30 hours, promoting both nuclear and cytoplasmic maturation.

06

What researchers measure

Primary outcomes

  1. Oocyte Maturation Rate = Number of MII oocytes / Number of COCs retrieved, compared to published data on conventional IVM for similar maternal age and PCOS indications.

    Time frame: From enrollement to 56 hours after the end of treatrment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Oct 2028, 29 months after the start.

Of 205 non-industry interventional studies with no phase under Polycystic Ovary Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 29 months is above that.

Counting every sponsor, half of 220 studies reached it within 17 months; a quarter within 7 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2026
First posted
Nov 20, 2026
StartActual
Apr 8, 2026
Primary completionEst.
Oct 1, 2028
CompletionEst.
Nov 30, 2030
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07951554
Lead sponsor
Hospital St. Joseph, Marseille, France
Responsible party
Sponsor
First posted
Nov 20, 2026
Start date
Apr 8, 2026
Primary completion
Oct 1, 2028 (estimated)
Completion
Nov 30, 2030 (estimated)
Last update
Nov 20, 2026

Study contacts

Aïda GASMI
Contact
agasmi2@hopital-saint-joseph.fr
+33 488731073

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion